In addition, the main signaling pathways involved in the treatment of GC were identified by KEGG enrichment analysis, including chemical carcinogenesis-receptor activation (hsa05207), neuroactive ligand-receptor interaction (hsa04080), calcium signaling pathway (hsa04020), AGE-RAGE signaling pathway in diabetic complications (hsa04933), cAMP signaling pathway (hsa04024), and PI3K-Akt signaling pathway (hsa04151) (Figures 6(a) and 6(b)). This evidence concerns the gene AKT1 and gastric cancer.